High altitude pulmonary edema

Area of Science:

• Physiology
• Altitude Medicine
• Pulmonary Medicine

Background:

• High-altitude pulmonary edema (HAPE) is a serious condition affecting individuals ascending to altitudes above 2,500-3,000 meters.
• The illness typically manifests 2-5 days after acute exposure and is characterized by pulmonary edema.
• Key determinants include altitude, ascent speed and mode, and individual susceptibility.

Purpose of the Study:

• To explore the pathophysiological mechanisms underlying high-altitude pulmonary edema (HAPE).
• To investigate the role of pulmonary artery pressure and inflammatory responses in HAPE development.
• To identify factors contributing to HAPE in susceptible individuals.

Main Methods:

• Review of clinical presentations and diagnostic findings in HAPE patients.
• Analysis of physiological parameters including pulmonary artery pressure (Ppa) and wedge pressure.
• Examination of bronchoalveolar lavage findings to assess inflammatory responses and capillary permeability.

Main Results:

• Chest imaging reveals patchy, predominantly peripheral edema distribution.
• Normal resting wedge pressure contrasts with an excessive rise in Ppa preceding edema.
• Bronchoalveolar lavage indicates an inflammatory response and increased capillary permeability in advanced HAPE.
• High Ppa in susceptible individuals without edema suggests additional factors are involved.

Conclusions:

• Excessive rise in pulmonary artery pressure (Ppa) is a critical pathophysiological factor in HAPE.
• Inflammatory response and/or decreased fluid clearance may be necessary for edema formation in susceptible individuals.
• Immediate descent is the primary treatment for HAPE; nifedipine is an alternative if descent is impossible and oxygen is unavailable.